Podcast | Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)

Course Title for Certificate
Name

First NameLast Name
Email
example@example.com
What best describes your title?

Other
If PharmD, DOB

MonthDayYear
2 digit month, 2 digit day, 4 digit yearDate
If PharmD, NABP ID#:
How many years have you been in practice?
1. Which of the following statements is false?
2. An advantage of CAR T-cell treatment in systemic lupus erythematosus (SLE) is:
3. A major disadvantage of autologous CAR T-cell treatment in SLE is:
How many patients do you currently see each month regarding severe refractory systemic lupus erythematosus (SLE)?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the pathophysiology and mode of action of CAR T-cell therapy
Review the current clinical options, unmet needs, and emerging therapies for patients with severe, refractory systemic lupus erythematosus
Analyze the clinical trial data and clinical applications of CAR T-cell therapy to treat patients with severe, refractory SLE
Develop strategies to incorporate patient shared decision making when discussing CAR T-cell therapy for SLE

Please provide us with feedback regarding your experience at the activity:

Do you feel this activity was fair, balanced, and free of commercial bias?
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
What factors beyond clinical care that effect the health of your patients does your team experience?
Attestation:

AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. AcademicCME designates this enduring material for a maximum of 1.25 CNE Contact Hours. AcademicCME designates this continuing education activity for 1.25 CPE Contact Hours (.125 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-25-032-H01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.
Date

MonthDayYear
2 digit month, 2 digit day, 4 digit yearDate
Credits
Should be Empty: